Given that Galectin-9 is specifically expressed by NPC cells, Galectin-9/TIM3/Foxp3 interaction may serve as a potential target for overcoming PD-1/PD-L1 drug resistance. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.